ReviewAnnual review of animal biosciences2016
Dogs as a Model for Cancer.
Review in Annual review of animal biosciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
140 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- The role of COX expression in the prognostication of overall survival of canine and feline cancer: A systematic review.Veterinary medicine and science · 2021Pooled it
- Establishment of Patient-Derived Xenotransplant and Cell Line Models for Canine B-Cell Lymphoma.Cells · 2026Article
- Preclinical study of an optimized AAV cancer vaccine in a spontaneous canine model of oral melanoma.Molecular therapy. Oncology · 2026Article
- Cross-Species Transcriptomic and Network Analysis of Human and Canine Diffuse Large B-Cell Lymphoma Identifies a Conserved Replication-DNA Damage Module for Drug Repurposing.Veterinary and comparative oncology · 2026Article
- Critical Questions in Genomic Diagnostics for Veterinary Oncology: What We Need to Know.Veterinary and comparative oncology · 2026Review
- Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease.Molecular oncology · 2026Article
- OptimizedJournal of veterinary science · 2026Article
- Impact of preanalytical factors on liquid biopsy in the canine cancer model.Communications medicine · 2026Article
- Nanoparticulate Immunoactive Complex for Local Chemoimmunotherapy: From Murine Models to Pilot Canine Study.Cancer research communications · 2026Article
- SatTCR: a pipeline for performing saturation analysis of the T cell receptor repertoire and a case study of a healthy canine.MethodsX · 2026Article
- Leveraging Dog Models to Uncover Human Cancer Insights.Research square · 2026Article
- Article
- Blood biomarkers and breed genetics of aging in pet dogs.bioRxiv : the preprint server for biology · 2026Article
- Comparative Cancer Genetics and Veterinary Therapeutics in Dogs and Cats: A Species-Aware Framework for Comparative Oncology.Life (Basel, Switzerland) · 2026Review
- Metabolomic profiling and anti-tumor function of canine NK cells in tumor interaction.BMC veterinary research · 2026Article
- Comparative Analysis of Cell-Free DNA Fragmentation Patterns in Canines with Sarcoma and Tumor-Free Canines and Humans.Cancer research communications · 2026Article
- Factors influencing malignant tumor development in cats from a multicenter retrospective study.Scientific reports · 2026Article
- Case Report: Multiple mammary carcinomas in a young dog with estrus-associated hyperglycemia: clinicopathological findings and glycemic normalization after ovariohysterectomy.Frontiers in veterinary science · 2026Article
- Patient-derived xenograft models: Current status, challenges, and innovations in cancer research.Genes & diseases · 2025Review
80 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Spontaneous cancers in client-owned dogs closely recapitulate their human counterparts with respect to clinical presentation, histological features, molecular profiles, and response and resistance to therapy, as well as the evolution of drug-resistant metastases. In several instances the incorporation of dogs with cancer into the preclinical development path of cancer therapeutics has influenced outcome by helping to establish pharmacokinetic/pharmacodynamics relationships, dose/regimen, expected clinical toxicities, and ultimately the potential for biologic activity. As our understanding regarding the molecular drivers of canine cancers has improved, unique opportunities have emerged to leverage this spontaneous model to better guide cancer drug development so that therapies likely to fail are eliminated earlier and therapies with true potential are optimized prior to human studies. Both pets and people benefit from this approach, as it provides dogs with access to cutting-edge cancer treatments and helps to insure that people are given treatments more likely to succeed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.